German pharmaceutical giant Bayer has inked a global exclusive license and collaboration deal with San Diego-based Kumquat Biosciences, valued at over $1.3 billion, to develop and commercialize a KRAS G12D inhibitor. This inhibitor targets one of the most prevalent oncogenic KRAS variants found in pancreatic, colorectal, and lung cancers, which have historically been considered 'undruggable'. Kumquat will conduct initial Phase 1a clinical trials before Bayer advances further development and commercialization. The agreement highlights increasing industry focus on precision oncology and addresses a significant unmet need for therapies against KRAS-driven tumors. Bayer’s commitment strengthens its early precision oncology pipeline, with the deal encompassing upfront payments, milestones, and royalties.